TSA Opt-Out t-shirt

On my latest trip home, I chose to opt-out of the “naked scanner” and as I was getting groped my free massage, I thought, “what a great idea for a T-Shirt”. So, without further adieu, presenting the all new, I Opted Out t-shirt from Zazzle. Its customizable in color, font, etc. Have fun, and opt out for you massage the next time you travel.

Opt Out T-shirt

On another note, during my massage, I asked the agent if he know how asinine this actually was, and he whispered nice and slowly, “Yes”.



Get 1000 rollover minutes from AT&T

Word on the street, and at least two different blogs are reporting that AT&T is giving away 1000 rollover minutes to loyal customers. How do you take advantage of this offering? The fine details aren’t clear, but its possible to get the process started by texting the word “yes” to 11113020.

Chipmunk in Slow Motion

This chipmunk reminds me of me when I wake up in the morning.


Apple and AT&T renew vows in secret

Fresh off the presses… Apple has release a new line of AT&T specific phones just in time for Valentines day.

If the NASDAQ can’t secure its network, what hope do we have??

This completely terrifies me from a security perspective, especially in context with the volumes of data that organizations are currently in the process of putting up into the cloud. If “the NASDAQ” can’t guarantee security in this environment, what hope do those of us working with hardware and resources that are a tiny fraction of what the NASDAQ must have?

According to this report, “Hackers were able to access data from the company’s Directors Desk product, which is a cloud-based service NASDAQ Group offers to companies that have their securities listed on its index, which allows users to securely share documents.”

Xconomy: Open Letter to Sanofi re: Genzyme Buyout

Steve Dickman, a former venture capitalist, the CEO of CBT Advisors and author of Boston Biotech Watch recently penned an open letter to the CEO of Sanofi, pleading with him not to overlook the talent within the R&D organization of Genzyme. He further suggests that the combined entity, which I’ll now call Sanofizyme, create a VC fund (akin to SROne, Lily Ventures, Novartis Venture Fund, etc) that would provide a “transition” for these employees, and prods that this fund needs serious skin in the game, “at least $150 million to $200 million”. He further mentions that by implementing the traditional syndicated deal structures it would be possible to fund about six to eight preclinical deals through early clinical development or three or four deals to proof-of-concept.

I would like to stir up the pot a bit, and add a different perspective to this idea. Assuming the goals of a traditional Pharma VC should be to develop a nice pipeline of external candidates that either work in synergy with, or at least complement the internal portfolio, this would certainly meet the need, BUT there is no added benefit as is typically seen when these candidates come from a comprehensive external due diligence process. It’s also not a secret that among the typical LP-based-ROI aims of a Pharma VC, they are tasked with scouring the landscape for who might have the potential to steal some of the thunder from any of the Company’s blockbuster pipeline. Its also fairly likely, the traditional Pharma VC, like their Pharma parents, subscribe to the notion of innovation driven by acquisition.

Consequently, and more to my point, a traditional Pharma VC approach on the part of Sanofizyme won’t work if they focus entirely on their own internal assets ONLY. What would be truly innovative and unique would be to create a hybrid approach, VC/incubator (hopefully Gregory Huang isn’t reading this), in which the parent Sanofizyme contributes the core $200M, which is then leveraged with some type of regional (state or country — I’m ambivalent) matching funds. Frankly, if that doesn’t work in Boston, take it somewhere that will match that $200M, or at least part of it. There are plenty of examples of groups (Korea, Singapore, China, etc etc) outside Boston and even the US that are interested in getting in on this specific type of action. Then, let this hybrid Pharma-Regional-VC-ubator utilize the R&D experts from the seed partner, in combination with a serious business development/VC due diligence team, in order to bring in a variety of external technologies (hopefully to some extent from smaller innovative start-up companies that are in such dire need of funding) that would create winning companies with broad pipelines and solid technology.

What’s all the fuss about FB’s sales tactics…

As the world becomes increasingly more reliant on google, facebook, etc, so much so that they have become action verbs in common language, our general discontent with such mega-conglomerates grows. It reminds me to a certain extent of the discontent a teenager has for his parents who provide him or her everything but still has to, in order to maintain some social conformity exhibit disdain for authority. Along the same lines, honestly, I’d be interested to know if anyone really truly cares that Facebook would syndicate, sell, or otherwise monetize your posts. Or is it more of a socially acceptable jab at the mother-ship, something worthwhile that everyone can unite together to have an opinion on. Either way is fine with me, I just find it somewhat funny that something someone finds so useful, somewhat indispensable would be given a hard time for growing the business channels, without harming the user experience. IF Facebook started charging its USERS to read posts from your friends, now that’s a whole new ballgame… but until then, I’m happy for them to make money, and translate those earnings into new features for all of us.